|
[1]BUGIANESI E, SALAMONE F, NEGRO F.The interaction of metabolic factors with HCV infection:does it matter?[J].J Hepatol, 2012, 56 (Suppl 1) :s56-s65.
|
|
[2]ADINOLFI LE, RESTIVO L, ZAMPINO R, et al.Chronic HCV infection is a risk of atherosclerosis.Role of HCV and HCV-related steatosis[J].Atherosclerosis, 2012, 221 (2) :496-502.
|
|
[3] FAN JG.Strengthen the research and management of the relationship of liver diseases with metabolic syndrome[J].Chin J Hepatol, 2013, 21 (2) :93-95. (in Chinese) 范建高.加强代谢综合征与肝病关系及其对策的研究[J].中华肝脏病杂志, 2013, 21 (2) :93-95.
|
|
[4]XING XY, YANG WY.Relationship between metabolic syndrome and liver dliseases[J].Chin J Pract Intern Med, 2011, 31 (9) :659-660. (in Chinese) 邢小燕, 杨文英.代谢综合征与肝病[J].中国实用内科杂志, 2011, 31 (9) :659-660.
|
|
[5]Metabolic Syndrome Study Group, Chinese Diabetes Society, Chinese Medical Association.Recommendations on metabolic syndrome of Chinese Diabetes Society, Chinese Medical Association[J].Chin J Diabetes, 2004, 12 (3) :5-10. (in Chinese) 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志, 2004, 12 (3) :5-10.
|
|
[6]YANG T, CHU CH, HSU CH, et al.Impact of metabolic syndrome on the incidence of chronic kidney disease:a Chinese cohort study[J].Nephrology (Carlton) , 2012, 17 (6) :532-538.
|
|
[7] BUGIANESI E, SALAMONE F, NEGRO F.The interaction of metabolic factors with HCV infection:does it matter?[J].J Hepatol, 2012, 56 (Suppl 1) :s56-s65.
|
|
[8]NEGRO F.Steatosis and insulin resistance in response to treatment of chronic hepatitis C[J].J Viral Hepat, 2012, 19 (Suppl 1) :42-47.
|
|
[9]MEHTA SH, BRANCATI FL, SULKOWSKI MS, et al.Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States[J].Ann Intern Med, 2000, 133 (8) :592-599.
|
|
[10]VIGANO M, VERGANI A, TROMBINI P, et al.Insulin resistance influence iron metabolism and hepatic steatosis in type II diabetes[J].Gastroenterology, 2000, 118 (5) :986-987.
|
|
[11]JARMAY K, KARACSONY G, NAGY A, et al.Changes in lipid metabolism in chronic hepatitis C[J].World J Gastroenterol, 2005, 11 (41) :6422-6428.
|
|
[12]CASTERA L, CHOUTEAU P, HEZODE C, et al.Hepatitis C virus-induced hepatocellular steatosis[J].Am J Gastroenterol, 2005, 100 (3) :711-715.
|
|
[13]ZHAO XN, LI HY, BAI ZZ, et al.Clinical analysis of 109 cases of hepatitis C virus infection In patients with the metabolic syndrome[J].Chin J Lab Disgn, 2011, 15 (11) :1866-1868. (in Chinese) 赵晓南, 李红艳, 白贞子, 等.109例丙型肝炎病毒感染患者合并代谢综合征的临床分析[J].中国实验诊断学, 2011, 15 (11) :1866-1868.
|
|
[14]LI M, WANG Q, CHENG J, et al.Regulation of cholesterol metabolism in HepG2 cells by HCV core protein via SREBP2 pathway[J].Hepatol Int, 2013, 7 (Suppl 1) :s322-s323.
|
|
[15]PATEL A, HARRISON SA.Hepatitis C virus infection and nonalcoholic steatohepatitis[J].Gastroenterol Hepatol (N Y) , 2012, 8 (5) :305-312.
|
|
[16]ROMERO-GMEZ M, FERNANDEZ-RODRGUEZ CM, ANDRADE RJ, et al.Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C[J].J Hepatol, 2008, 48 (5) :721-727.
|
|
[17]LECUBE A, HERNANDEZ C, SIMO R, et al.Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C[J].Am J Gastroenterol, 2007, 102 (10) :2189-2195.
|
|
[18]CORTEZ-PINTO H.Concluding remarks:metabolic syndrome, liver and HCV[J].Aliment Pharmacol Ther, 2005, 22 (Suppl 2) :83-85.
|
|
[19]OLIVEIRA LP, JESUS RP, BOULHOSA RS, et al.Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes[J].Clinics (Sao Paulo) , 2012, 67 (3) :219-223.
|
|
[20]WEI L, LIU JK.Influence of lipid metabolism on-the antiviral response in patients with chronic hepatitis C[J/CD].Chin J Exp Clin Infect Pis:Electronic Edition, 2012, 6 (5) :447-450. (in Chinese) 魏莉, 刘江奎.脂类代谢对慢性丙型肝炎抗病毒治疗疗效的影响[J/CD].中华实验和临床感染病杂志:电子版, 2012, 6 (5) :447-450.
|
|
[21]WESTIN J, LAGGING M, DHILLON AP, et al.Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection[J].J Viral Hepat, 2007, 14 (1) :29-35.
|
|
[22]ROMANO M, VACANTE M, CRISTALDI E, et al.L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin[J].Dig Dis Sci, 2008, 53 (4) :1114-1121.
|
|
[23]SEZAKI H, SUZUKI F, AKUTA N, et al.An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads[J].Intervirology, 2009, 52 (1) :43-48.
|
|
[24]MILAZZO L, CARAMMA I, MAZZALI C, et al.Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients:an open-label randomized controlled study[J].J Antimicrob Chemother, 2010, 65 (4) :735-740.
|
|
[25]BADER T, FAZILI J, MADHOUN M, et al.Fluvastatin inhibits hepatitis C replication in humans[J].Am J Gastroenterol, 2008, 103 (6) :1383-1389.
|
|
[26]KAWAGUCHI T, IDE T, TANIGUCHI E, et al.Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2[J].Am J Gastroenterol, 2007, 102 (3) :570-576.
|
|
[27]MELLO V, CRUZ T, NUNEZ G, et al.Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin[J].J Med Virol, 2006, 78 (11) :1406-1410.
|
|
[28]TAHRANI A, BOWLER L, SINGH P, et al.Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis C[J].Eur J Gastroenterol Hepatol, 2006, 18 (3) :291-293.
|
DownLoad: